China’s pharmaceutical industry is producing results that would have seemed implausible five years ago. Of the 19 innovative drugs cleared by China’s National Medical Products Administration (NMPA) for sale so far in 2026, 15 came from domestic Chinese companies, according to South China Morning Post reporting published on May 27. The figure, drawn from the NMPA’s own website as of May 21, reflects a structural shift in China’s drug development capabilities that has been building for a decade and is now producing measurable commercial output.
The approvals include sonrotoclax, developed by global biopharmaceutical firm BeOne, for treating certain adult blood cancers, a drug that illustrates the increasingly blurred line between Chinese and international biotech, as BeOne operates at the intersection of Chinese capital and global scientific talent. The NMPA has overhauled its approval process to accelerate the path to market for homegrown innovative drugs, a reform reported by state media on Wednesday.
From 48 to 76: The Approval Acceleration
The pace of approvals is accelerating rapidly. China approved 76 innovative drugs in 2025, up from 48 in 2024 — a 58% increase in a single year. The 2026 pace, with 19 approvals in roughly five months, suggests the annual total could approach or exceed 2025’s record. The NMPA’s process reforms are a direct cause: by streamlining review timelines and creating dedicated fast-track pathways for drugs addressing unmet medical needs, the regulator has reduced the time between clinical trial completion and market authorization.
This acceleration matters for AI because drug discovery is one of the most data-intensive and computationally demanding applications of artificial intelligence. As EastFrontier has reported, China has mandated 32 measures to accelerate AI drug discovery and surgical robots, and Chinese scientists used a supercomputer to cut drug screening from years to seconds. The approval data is the downstream validation of those upstream investments: AI-assisted drug discovery is producing drugs that are reaching patients.
The $60 Billion Licensing Surge
The most striking data point in the SCMP report is the cross-border licensing figure. Chinese biotech firms struck a record US$60 billion in cross-border licensing deals in the first quarter of 2026 alone, as multinational pharmaceutical corporations snapped up early-stage drugs from China’s pipeline. The Q1 2026 figure represents a 73% year-on-year surge and equalled nearly half of the US$135.7 billion in total out-licensing agreements signed across all of 2025. The source for the licensing deal figure is NMPA data.
The licensing boom reflects a fundamental change in how the global pharmaceutical industry views Chinese drug development. For most of the past two decades, multinational companies licensed drugs into China, bringing their products to a large and growing market. The direction of flow is now reversing: global companies are licensing Chinese-developed drugs out of China, paying substantial upfront fees and milestone payments for access to molecules that Chinese companies have discovered and de-risked through early-stage clinical trials.
Fosun Pharma’s R&D investment illustrates the capital commitment behind this output. The company invested 4.3 billion yuan (US$634 million) in innovative drug R&D last year, up approximately 16% from 2024, with more than 80% of its total research budget allocated to innovative drugs rather than generics. For the first time, China’s government work report for 2026 elevated the pharmaceutical sector to a national economic growth engine, a designation that signals sustained policy support and capital allocation priority.
The regulatory reform dimension of the story is as important as the scientific one. The NMPA’s process overhaul, which state media reported on Wednesday — is designed to accelerate the path from clinical trial completion to market authorization for home-grown innovative drugs. Faster approvals reduce the time-to-revenue for drug developers, which in turn makes the economics of early-stage drug discovery more attractive to investors. The $60 billion in Q1 2026 licensing deals is partly a consequence of this regulatory improvement: multinational companies are more willing to pay large upfront fees for Chinese-developed drugs when they can see a credible regulatory pathway to global commercialization.
The AI connection runs through the entire pipeline. AI-assisted drug discovery tools reduce the cost and time of identifying viable drug candidates. AI-powered clinical trial design tools improve the efficiency of the human trials that precede regulatory submission. And AI-driven regulatory intelligence tools help companies navigate the NMPA’s approval process more efficiently. China’s biotech boom is not simply a story about scientific talent and capital, it is a story about AI compressing the timelines and costs of every stage of the drug development process simultaneously.